Table 2.

EMT-TFs expression according to CTC count and treatment

SubgroupsData available (no. of patients)EMT-TF+ CD326+, n/N (%)EMT-TF+ CD45, n/N (%)
No. of CTCs
 0124/6 (66.7)6/12 (50)
 1–473/3 (100)3/7 (42.9)
 ≥531/1 (100)3/3 (100)
Trastuzumab-naïve (group 1)95/6 (83.3)8/9 (88.9)
Trastuzumab-treated (group 2)1810/11 (90.9)8/18 (44.4)